Savara Pharmaceuticals

Savara Pharmaceuticals

Savara Pharmaceuticals

Savara Pharmaceuticals develops an inhaled antibiotic for MRSA infection inCystic Fibrosis
Type
B2c
Founded
2007
Raised
$103.9M
Follow us
Alexa global traffic share
26 Oct 2017
$47,000,000
Post-IPO equity
01 Mar 2016
$20,000,000
Venture capital (Series C)

Savara Pharmaceuticals Closes $20M Series C Financing

FinSMEs
+1
06 Oct 2014
$10,000,000
Venture capital
Boutique investment bank
12 Jun 2014
$4,493,581
Debt financing
21 Mar 2013
$7,400,000
Venture capital (Series B)